Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.77 |
| ▸ | CDK1 | P06493 | 16/20 | 0.77 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.77 |
| ▸ | AURKA | O14965 | 1/20 | 0.77 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.77 |
| ▸ | CDK4 | P11802 | 1/20 | 0.77 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.77 |
| ▸ | CCND1 | P24385 | 1/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.77 |
| ▸ | CDK7 | P50613 | 1/20 | 0.77 |
| ▸ | CDK9 | P50750 | 1/20 | 0.77 |
| ▸ | CCNH | P51946 | 1/20 | 0.77 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.77 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.77 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.77 |
| ▸ | CCNA2 | P20248 | 18/20 | 0.66 |
| ▸ | CCNA1 | P78396 | 17/20 | 0.66 |
| ▸ | CCNB2 | O95067 | 14/20 | 0.63 |
| ▸ | CCNB3 | Q8WWL7 | 14/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060307 | 1.00 | CDK2 (0.77) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL6789620 | 0.91 | CDK2 (0.76) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL6904174 | 0.88 | CDK2 (0.75) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL6789333 | 0.87 | CDK2 (0.74) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL29399474 | 0.87 | CDK2 (1.00) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL6787523 | 0.86 | CDK2 (0.63) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL6790184 | 0.86 | CDK2 (0.75) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL6789156 | 0.86 | CDK2 (0.75) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL29644959 | 0.86 | CDK2 (0.75) | CDK2CDK1CCNB1AURKACCNT1 | |
| SCHEMBL6790670 | 0.85 | CDK2 (0.61) | CDK2CDK1CCNB1AURKACCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | claimed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | claimed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-9234178-B2 | Differentiation of human pluripotent stem cells | JANSSEN BIOTECH, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-2346988-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | Centocor Ortho Biotech Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100112693-A1 | Differentiation of Human Embryonic Stem Cells | CENTOCOR ORTHO BIOTECH, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010051223-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | CENTOCOR ORTHO BIOTECH INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | CDK2 512/4885CDK1 227/4885CCNB1 147/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | CDK2 441/4885CDK1 265/4885CCNB1 77/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | CDK2 512/4885CDK1 227/4885CCNB1 147/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | CDK2 1640/4885CDK1 1489/4885CCNB1 275/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | CDK2 13/4885CDK1 4/4885CCNB1 20/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | CDK2 441/4885CDK1 265/4885CCNB1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.